TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Psychological impact of in utero fetal death
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Professional impact of in utero fetal death
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cow's milk-related symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Direction change performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vehnam Anxiety Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frankl behavior rating scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FLACC Pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venham Scale of Dental behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC0-t) of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of undetectable minimal residual disease (uMRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Cerebral Doppler velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vaccine Neutralizing Antibody Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total long acting opioid consumption in oxycodone equivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) of DBPR108 tablets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of DBPR108 tablets in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life(t1/2) of DBPR108 tablets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Right Heart Remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative Number of New Active Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post-Extubation Cough Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Curve (AUC) of Diagnostic Model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes of hyperactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes of attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Symptoms related to Specific Illness or Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of intraoperative fentanyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of clipped nodes detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Harrell concordance index (C-index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in resting surface EMG activity (amplitude, RMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standardized drinks per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBX2660-related treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Hepatic biomarker alanine aminotransferase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hepatic Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Hepatic Steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of ventilator support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time To Peak Torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best overall response rate (ORR)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative NRS pain score at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 area under the curve from 0-8 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma Area Under the Curve (AUC(0 to 36hr)) for Vildagliptin and Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of donor derived genes in tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: uptake of Pre-exposure prophylaxis of HIV (PrEP)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pancreatic polypeptide concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Wrist function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Secondary graft failure
Endpoint domain: Mortality/survival
Primary endpoint: Recruitment and consent rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in Nausea score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body-weight change in %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Completion of cardiac rehab sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: postprandial blood glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postprandial blood insulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post interventional pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of First Pass Reperfusion Effect (FPE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Rate of symptomatic intracranial hemorrhage (sICH)
Endpoint domain: Adverse events/effects
Primary endpoint: GMFCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients experiencing at least one Serious Adverse Event (SAE) during treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients experiencing at least one Adverse Event of Special Interest (AESI) during treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with P. vivax malaria who correctly receive all components of the revised case management package
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in medication injection/delivery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterization of serum proteome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective remission rates (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventricular pacing threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Caring Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychiatric Nurses Job Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Lower Incisors Inclination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fMRI during radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of the delivered diet: Patient opinion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerability of the delivered diet: Proportion of meals consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of reduction of Ki67 index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mental health - psychiatric symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental health - Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mental health - Self-report questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Level of suicidal intent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerance of tolfenamic acid
Endpoint domain: Adverse events/effects
Primary endpoint: Complete remission/CR with partial hematologic recovery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Velocity of Gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General safety (number, frequency, severity, seriousness and duration of adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in RV/LV diameter ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tolerance of each type of biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PROMS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Behavior Rating Inventory of Executive Function composite score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of patients with local injection-related reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Length in millimetres of the centre of pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of the ellipse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inclination of the ellipse in degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of anticipated or un-anticipated serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in C-reactive protein (CRP), TNF-α, interleukin (IL)-6, IL-8 and IL-10 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients having decrease in PAN-PROMISE score by at least 10 points at 72h after initiation of the drug
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PrEP Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in blood lactate concentration (BLa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Planimetric plaque index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Breath Alcohol Level (BrAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological resolution of NASH without worsening of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: ≥1 stage decrease in fibrosis stage with no worsening of NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Incidence of catheter-related thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Left ventricular end-systolic volume indexed to body surface area (LVESVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Implant Survivorship at 10 years follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Frequency and Incidence of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Progression-Free Survival at 12 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: Depression-Post intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety-Post intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fear of Childbirth-Post intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Massachusetts General Hospital Hairpulling Scale (MGH-HPS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-regulated learning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Objective Response Rate (ORR) by Response Evaluation Criteria In Solid Tumors (RECIST) V1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sustained Resolution of COVID-19 Signs and Symptoms Without Subsequent Symptom Recurrence or Disease Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static two-point discrimination (s2PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of infants with lactose intolerance (LI) misdiagnosed as cow milk protein allergy
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients receiving anti-tumor regimens
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cerebral MRI Microstructural abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total weight loss at 2 years > 30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total weight loss at 5 years > 30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short term postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Middle to long-term postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in SPPB total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunological response to the vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: platinum resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Acquisition of extended-spectrum betalactamase-producing enterobacteria
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery of probiotic strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Emergence Agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of favorable outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Positive and Negative Syndrome Scale - Excited (PEC) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of SAEs and TEAEs compared with placebo
Endpoint domain: Adverse events/effects
Primary endpoint: High-risk alcohol drinking days (HDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Depression Anxiety Stress Scales (DASS-21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Estimated Gastric volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Disability Rating Score (DRS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Platelet Concentration in the PRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of Clostridioides difficile infection (CDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Annualized incidence rate of moderate to severe acute exacerbations of chronic obstructive pulmonary disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of pre-term neonates that require endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Measurement of Th1, Th2 and Th17 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gastric antral surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants with Chronic Diarrhea Diagnosed with Microscopic Colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intensity of Bruising Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients reaching clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in student scores on the ICCAS
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Degree of epistaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in respiratory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Uptake of a modern contraceptive method
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Initiation of childbearing
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Academic Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vision at 12 months post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of closure of Caesarean section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in symptom severity of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in WOMAC Pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of GERD-HRQL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Experience of the postpartum
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Scientific Assessment Scale of Skin Quality (SASSQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Physician Global Aesthetic Improvement Scale (PGAIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent improvement of skin quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: short-term survival outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Arterial Compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Therapeutic efficacy (clinical success)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Grade >= 3 Related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Biologically effective dose (BED) of eltanexor in combination with venetoclax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune cell phenotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Parasite load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Concentration of interferon-gamma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of tumor necrosis factor-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of blood malondialdehyde
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of blood protein carbonyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Note comprehension
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Acceptability by actively treated participants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of light and moderate intensity exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Acceptability of light and moderate intensity exercise
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerability of light and moderate intensity exercise
Endpoint domain: Adverse events/effects
Primary endpoint: Allergens with positive skin reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of lead in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: World Health Organization Quality of Life - Brief Version (WHOQOL-BREF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time from collapse to ECPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number/prevalence of variants with clinical significance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number/prevalence of alterations by type (SNVs, CNVs, fusions)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CENP-V levels in oocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Insulin Requirements at 6 Months Post-Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Overall Hospital Rating
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Perceived stress scale -10 (PSS-10)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing